The Clorox Company (NYSE:CLX) Shares Bought by Somerset Trust Co

Somerset Trust Co raised its position in The Clorox Company (NYSE:CLX) by 8.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,361 shares of the company’s stock after acquiring an additional 1,147 shares during the quarter. Somerset Trust Co’s holdings in Clorox were worth $2,262,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Integral Investment Advisors Inc. raised its stake in shares of Clorox by 4.1% during the fourth quarter. Integral Investment Advisors Inc. now owns 1,718 shares of the company’s stock valued at $279,000 after purchasing an additional 67 shares in the last quarter. Sound View Wealth Advisors Group LLC raised its stake in shares of Clorox by 6.1% during the fourth quarter. Sound View Wealth Advisors Group LLC now owns 1,345 shares of the company’s stock valued at $218,000 after purchasing an additional 77 shares in the last quarter. Wedbush Securities Inc. raised its stake in shares of Clorox by 1.2% during the fourth quarter. Wedbush Securities Inc. now owns 7,624 shares of the company’s stock valued at $1,238,000 after purchasing an additional 94 shares in the last quarter. Global X Japan Co. Ltd. raised its stake in shares of Clorox by 3.0% during the fourth quarter. Global X Japan Co. Ltd. now owns 3,272 shares of the company’s stock valued at $531,000 after purchasing an additional 95 shares in the last quarter. Finally, Aviance Capital Partners LLC raised its stake in shares of Clorox by 3.2% during the fourth quarter. Aviance Capital Partners LLC now owns 3,180 shares of the company’s stock valued at $516,000 after purchasing an additional 100 shares in the last quarter. Institutional investors and hedge funds own 78.53% of the company’s stock.

Clorox Trading Up 0.6%

Shares of CLX opened at $131.76 on Friday. The business’s 50-day moving average price is $138.30 and its 200 day moving average price is $151.24. The stock has a market capitalization of $16.24 billion, a P/E ratio of 36.00, a P/E/G ratio of 2.62 and a beta of 0.60. The Clorox Company has a 1-year low of $128.79 and a 1-year high of $171.37. The company has a current ratio of 0.94, a quick ratio of 0.60 and a debt-to-equity ratio of 20.52.

Clorox (NYSE:CLX) last issued its quarterly earnings results on Monday, May 5th. The company reported $1.45 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.12). The company had revenue of $1.67 billion during the quarter, compared to analysts’ expectations of $1.74 billion. Clorox had a return on equity of 316.87% and a net margin of 6.38%. The company’s revenue for the quarter was down 8.0% compared to the same quarter last year. During the same period in the prior year, the business posted $1.71 EPS. Analysts expect that The Clorox Company will post 7.15 earnings per share for the current year.

Insider Buying and Selling at Clorox

In other Clorox news, Director Pierre R. Breber bought 4,000 shares of the stock in a transaction on Wednesday, May 7th. The shares were bought at an average price of $136.57 per share, with a total value of $546,280.00. Following the purchase, the director now directly owns 4,000 shares in the company, valued at $546,280. The trade was a ? increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.57% of the company’s stock.

Analyst Upgrades and Downgrades

CLX has been the topic of several research reports. Wells Fargo & Company dropped their price target on shares of Clorox from $145.00 to $142.00 and set an “equal weight” rating on the stock in a research report on Tuesday, May 6th. JPMorgan Chase & Co. dropped their price target on shares of Clorox from $151.00 to $144.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 6th. DA Davidson dropped their price target on shares of Clorox from $171.00 to $169.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 5th. UBS Group dropped their price target on shares of Clorox from $176.00 to $154.00 and set a “neutral” rating on the stock in a research report on Thursday, April 17th. Finally, Barclays dropped their price target on shares of Clorox from $134.00 to $129.00 and set an “underweight” rating on the stock in a research report on Wednesday, May 7th. Three equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and one has given a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $151.23.

About Clorox

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.